true
Icon to close the modal
Support
Becton Dickinson Australia & New Zealand
Phone Icon
AU: 1800 656 100
NZ: 0800 572 468
Modal Close Icon
Icon to close thank you modal
Thank you for contacting our sales team!
A sales representive will get in touch with you shortly.
For more information, please visit our Contact Us page

AristaTM Absorbable Haemostat (AH)

Absorbable Haemostatic Particles

Contact Us
Arista-AH
Loading

Overview

Simple. Effective.

Arista™ AH is a 100% plant based absorbable surgical haemostatic powder derived from purified plant starch. The power of Arista™ AH lies in its Microporous Polysaccharide Haemospheres, a patented blood clotting technology.

Arista™ AH is indicated in surgical procedures (except neurologic and ophthalmic) as an adjunctive haemostatic device to assist when control of capillary, venous, and arteriolar bleeding by pressure, ligature, and other conventional procedures are ineffective or impractical.

Features and Benefits
SIMPLE
SIMPLE
  • No mixing and no refrigeration
  • Ready on demand and 5 year shelf life 
  • Pop the cap and apply powder directly to the bleeding site1
EFFECTIVE
EFFECTIVE
  • Clotting process begins on contact, regardless of patient’s coagulation status2
  • Complete haemostasis is achieved in minutes3
  • Provides broad area coverage on rough surfaces and in hard-to-reach areas

References

1 See full Instructions For Use for detailed application instructions.
2 Arista™ AH Instructions for Use.
3 Arista™ AH PMA P050038 Clinical Study.

INDICATIONS FOR USE

Arista™ AH is indicated in surgical procedures (except ophthalmic) as an adjunctive hemostatic device to assist when control of capillary, venous, and arteriolar bleeding by pressure, ligature, and other conventional procedures is ineffective or impractical.

CONTRAINDICATIONS

Do not inject or place Arista™ AH into blood vessels as the potential for embolization and death may exist.

WARNINGS

1. Safety and effectiveness of Arista™ AH has not been clinically evaluated in children, pregnant, and/or breast-feeding women. Because there have been reports of decreased amylase activity in newborns up to 10 months, absorption rates of Arista™ AH in this population may be longer than 48 hours.

2. Once hemostasis is achieved, excess Arista™ AH should be removed from the site of application by irrigation and aspiration particularly when used in and around foramina of bone, areas of bony confine, the spinal cord, and/or the optic nerve and chiasm. Arista™ AH swells to its maximum volume immediately upon contact with blood or other fluids. Dry, white Arista™ AH should be removed. The possibility of the product interfering with normal function and/or causing compression necrosis of surrounding tissues due to swelling is reduced by the removal of excess dry material.

3. This device has been designed for single use only. Reuse, resterilization, reprocessing and/or repackaging may compromise the essential material and design characteristics that are critical to the overall performance of the device and may lead to device failure which may result in injury to the patient. Reuse, reprocessing, resterilization, or repackaging may also create a risk of contamination of the device and/or cause patient infection or cross infection, including, but not limited to, the transmission of infectious diseases from one patient to another. Contamination of the device may lead to injury, illness, or death of the patient or end user.

4. Arista™ AH is not intended as a substitute for meticulous surgical technique and the proper application of ligatures or other conventional procedures for hemostasis.

5. Safety and effectiveness in ophthalmic procedures has not been established.

6. Arista™ AH should not be used for controlling post-partum bleeding or menorrhagia.

7. Arista™ AH should be used with caution in the presence of infection or in contaminated areas of the body. If signs of infection or abscess develop where Arista™ AH has been applied, re-operation may be necessary in order to allow drainage.

8. Discard device after use. This product may be a potential biohazard. Handle and dispose in accordance with accepted medical practice and applicable local, state, and federal laws and regulations.

PRECAUTIONS

1. Only physicians qualified in the appropriate surgical techniques should use this device.

2. The safety and effectiveness for use in neurological procedures has not been established through randomized clinical studies.

3. When Arista™ AH is used in conjunction with autologous blood salvage circuits, carefully follow instructions in the Administration section regarding proper filtration and cell washing.

4. Arista™ AH is intended to be used in a dry state. Contact with saline or antibiotic solutions prior to achieving hemostasis will result in loss of hemostatic potential.

5. Arista™ AH is supplied as a sterile product and cannot be resterilized. Unused, open containers of Arista™ AH should be discarded.

6. Do not apply more than 50g of Arista™ AH in diabetic patients as it has been calculated that amounts in excess of 50g could affect the glucose load.

7. Arista™ AH is not recommended for the primary treatment of coagulation disorders.

8. In urological procedures, Arista™ AH should not be left in the renal pelvis or ureters to eliminate the potential foci for calculus formation.

9. No testing has been performed on the use of Arista™ AH on bone surfaces to which prosthetic materials are to be attached with adhesives and is therefore not recommended.

ADVERSE REACTIONS

In a randomized prospective, concurrently controlled clinical trial, a total of 288 randomized patients received Arista™ AH or the Control (Gelatin Sponge with or without Thrombin). The most common recorded adverse events were pain related to surgery, anemia, nausea, and lab values out of normal range. The following is a complete list of adverse events reported in greater than 5% of the Arista™ AH treated patients. The corresponding adverse events for the Control group are listed for comparison. None of the adverse events that occurred were judged by the Data Safety Monitoring Board to be related to the use of Arista™ AH.

Products & Accessories
RELATED PRODUCTS NOT AVAILABLE
EIFUs
Resources

What is the Arista™ haemostatic agent?

  •  Topical haemostats include agents that act as a mechanical barrier to bleeding and provide a physical matrix for clotting, biologically active agents that catalyse coagulation, and combination therapies. 2
  • Haemostats can enhance clot formation and wound healing, and can be useful for controlling or preventing troublesome bleeding during surgical interventions where conventional methods of haemostasis are inadequate.2
  • Arista™ AH is an absorbable powdered haemostatic agent intended for application to surgical wound sites to control bleeding. It is a fine, dry, sterilised white powder that is biocompatible, non-pyrogenic, and typically absorbed within 24-48 hours." 

 

  • Arista™ AH is a 100% plant based absorbable surgical haemostatic powder derived from purified plant starch. The power of Arista™ AH lies in its Microporous Polysaccharide Haemospheres, a patented blood clotting technology. Consisting of microporous particles with a controlled pore size, the spheres are designed to act as a molecular sieve. The powerful osmotic action dehydrates and gels the blood on contact to accelerate the natural clotting process." 

How Arista™ AH Works & Is Used

Examples of surgeries that Arista™ AH can be used in include:

  • Cardiothoracic and cardiovascular
  • Vascular
  • Gynaecological
  • Urology
  • Orthopaedic
  • General
  • Plastic
  • Ear, Nose, Throat (ENT)

Advantages of Arista™ AH

  • A wide variety of topical haemostats are approved as adjunctive therapies in the maintenance of haemostasis during surgical procedures in which conventional methods are insufficient or not practical.2
  •  Potential cost benefits in terms of preventing the further utilisation of hospital resources to manage surgical bleeding. In addition to other patient blood management strategies, the intraoperative use of topical haemostats may reduce the need for transfusion of blood products (e.g., packed red blood cells, platelets, fresh frozen plasma) and reduce the duration of postoperative care (length of hospital stay) each of which is associated with substantial costs.2

Simple to Use

  • Ready on demand
  • Simply pop the cap and apply the powder directly to the bleeding site
  • No mixing and no refrigeration
  • Five-year shelf life4

Thrombin-Free

  • Synthesised from a purified plant starch
  • Thrombin-free, biocompatible and nonpyrogenic
  • Typically absorbed and cleared within 24–48 hours by amylases
  • Arista™ AH is the only currently available haemostat that is approved for cell salvage compatibility1,6,7

Effective Haemostat

  • The clotting process begins on contact, regardless of patient’s coagulation status
  • Complete haemostasis can be achieved in minutes5
  • Provides broad area coverage

Arista™ AH Results and Case Studies

PMA clinical trial (General, Orthopedic, Cardiac)

Cardiac & Vascular:

ENT:

General:

Urology

References

 

  1. Arista™ AH IFU
  2. Gabay, M. & Boucher, B.A. An essential primer for understanding the role of topical hemostats, surgical sealants, and adhesives for maintaining hemostasis. Pharmacotherapy 33, 935-955 (2013).
  3. Safety and effectiveness of ARISTA™ AH have not been clinically evaluated in children and pregnant women. Because there have been reports of decreased amylase activity in newborns up to 10 months, absorption rates of ARISTA™ AH in this population may be longer than 48 hours
  4. Data on file
  5. ARISTA™ AH PMA Clinical Study P050038
  6. BD Data on file. Preclinical data may not correlate to clinical performance in humans.
  7. When Arista™ AH is used in conjunction with autologous blood salvage circuits, a 40 μ cardiotomy reservoir, cell washing, and 40 μ transfusion filter must be used.

BD-53859

true
true